# A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

> **NCT04444752** · PHASE2 · COMPLETED · sponsor: **Connect Biopharm LLC** · enrollment: 226 (actual)

## Conditions studied

- Moderate-to-severe Atopic Dermatitis

## Interventions

- **DRUG:** CBP-201
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04444752
- **Lead sponsor:** Connect Biopharm LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-17
- **Primary completion:** 2021-07-28
- **Final completion:** 2021-09-22
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04444752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04444752, "A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04444752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*